A review of methods to monitor the modulation of mRNA stability: A novel approach to drug discovery and therapeutic intervention

Journal of Biomolecular Screening

Volumn 15, Issue 6, 2010, Pages 609-622

  Cheneval, Dominique ^a   Kastelic, Tania ^a   Fuerst, Peter ^b   Parker, Christian N ^b  

^a Novation Pharmaceuticals Inc   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ARE elements; assays; cell based assays; mRNA stability; reporter gene assays

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; BERBERINE; CYCLOSPORIN A; ERYTHROMYCIN; GLUCOCORTICOID; HYDROXYFASUDIL; MESSENGER RNA; OKADAIC ACID; PACLITAXEL; PAROXETINE; RADICICOL ANALOG A; RAPAMYCIN; RETINOIC ACID; RNA BINDING PROTEIN; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG;

DRUG MECHANISM; EUKARYOTIC CELL; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME ECHOGRAPHY; REVIEW; RNA STABILITY; BIOASSAY; DRUG DEVELOPMENT; DRUG SCREENING; GENETICS; HUMAN; PROCEDURES;

BIOLOGICAL ASSAY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; RNA STABILITY;

EUKARYOTA; MAMMALIA;

EID: 77955823838     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110365897     Document Type: Review

References (125)

1. Moore MJ: From birth to death: the complex lives of eukaryotic mRNAs. Science 2005 ; 309: 1514-1518.
2. Keene JD: RNA regulons: coordination of post-transcriptional events. Nat Rev Genet 2007 ; 8: 533-543.
3. Knight E. Jr, Anton ED, Fahey D., Friedland BK, Jonak GJ: Interferon regulates c-myc gene expression in Daudi cells at the post-transcriptional level. Proc Natl Acad Sci USA 1985 ; 82: 1151-1154.
4. Seitz M., Loetscher P., Fey MF, Tobler A.: Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol 1994 ; 33: 613-619.
5. Burchett SK, Weaver WM, Westall JA, Larsen A., Kronheim S., Wilson CN: Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol 1988 ; 140: 3473-3481.
6. Ross J.: mRNA stability in mammalian cells. Microbiol Rev 1995 ; 59: 423-450.
7. Wilusz CJ, Wormington M., Peltz SW: The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2001 ; 2: 237-246.
8. Malter JS: Regulation of mRNA stability in the nervous system and beyond. J Neurosci Res 2001 ; 66: 311-316.
9. Audic Y., Hartley RS: Post-transcriptional regulation in cancer. Biol Cell 2004 ; 96: 479-498.
10. Hollams EM, Giles KM, Thomson AM, Leedman PJ: mRNA stability and the control of gene expression: implications for human disease. Neurochem Res 2002 ; 27: 957-980.
11. Khabar KS: The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005 ; 25: 1-10.
12. Brewer G.: An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro. Mol Cell Biol 1991 ; 11: 2460-2466.
13. Shaw G., Kamen R.: A conserved AU sequence from the 3-2 untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986 ; 46: 659-667.
14. Shyu AB, Belasco JG, Greenberg ME: Two distinct destabilizing elements in the c-fos message trigger deadenylation as a first step in rapid mRNA decay. Genes Dev 1991 ; 5: 221-231.
15. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., Cerami A.: Identification of a common nucleotide sequence in the 3-2-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986 ; 83: 1670-1674.
16. Mullner EW, Kuhn LC: A stem-loop in the 3-2 untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm. Cell 1988 ; 53: 815-825.
17. Bakheet T., Williams BR, Khabar KS: ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic Acids Res 2006 ; 34: D111 - D114.
18. Chen CY, Shyu AB: AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995 ; 20: 465-470.
19. Veyrune JL, Campbell GP, Wiseman J., Blanchard JM, Hesketh JE: A localisation signal in the 3-2 untranslated region of c-myc mRNA targets c-myc mRNA and beta-globin reporter sequences to the perinuclear cytoplasm and cytoskeletal-bound polysomes. J Cell Sci 1996 ; 109: 1185-1194.
20. Liao B., Hu Y., Brewer G.: Competitive binding of AUF1 and TIAR to MYC mRNA controls its translation. Nat Struct Mol Biol 2007 ; 14: 511-518.
21. Lagnado CA, Brown CY, Goodall GJ: AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol Cell Biol 1994 ; 14: 7984-7995.
22. Zubiaga AM, Belasco JG, Greenberg ME: The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol 1995 ; 15: 2219-2230.
23. DeMaria CT, Brewer G.: AUF1 binding affinity to A+U-rich elements correlates with rapid mRNA degradation. J Biol Chem 1996 ; 271: 12179-12184.
24. Gillis P., Malter JS: The adenosine-uridine binding factor recognizes the AU-rich elements of cytokine, lymphokine, and oncogene mRNAs. J Biol Chem 1991 ; 266: 3172-3177.
25. Nakagawa J., Waldner HP, Meyer-Monard S., Hofstenge J., Jenö P., Moroni C.: AUH, a gene enconding an AU-specific RNA binding protein with intrinsic enoyl-CoA hydratase activity. Proc Natl Acad Sci USA 1995 ; 92: 2051-2055.
26. Bohjanen PR, Petryniak B., June CH, Thompson CB, Lindsten T.: An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3-2 untranslated region of lymphokine mRNA. Mol Cell Biol 1991 ; 11: 3288-3295.
27. Vakalopoulou E., Schaack J., Shenk T.: A 32-kilodalton protein binds to AU-rich domains in the 3-2 untranslated regions of rapidly degraded mRNAs. Mol Cell Biol 1991 ; 11: 3355-3364.
28. Zhang W., Wagner BJ, Ehrenman K., Schaefer AW, DeMaria CT, Crater D., et al. Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol Cell Biol 1993 ; 13: 7652-7665.
29. Katz DA, Theodorakis NG, Cleveland DW, Lindsten T., Thompson CB: AU-A, an RNA-binding activity distinct from hnRNP A1, is selective for AUUUA repeats and shuttles between the nucleus and the cytoplasm. Nucleic Acids Res 1994 ; 22: 238-246.
30. Veyrune JL, Carillo S., Vie A., Blanchard JM: c-fos mRNA instability determinants present within both the coding and the 3-2 non coding region link the degradation of this mRNA to its translation. Oncogene 1995 ; 11: 2127-2134.
31. Chen CY, Del Gatto-Konczak F., Wu Z., Karin M.: Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science 1998 ; 280: 1945-1949.
32. Chen CY, Gherzi R., Andersen JS, Gaietta G., Jurchott K., Royer HD, et al. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev 2000 ; 14: 1236-1248.
33. Winzen R., Kracht M., Ritter B., Wilhelm A., Chen CY, Shyu AB, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 1999 ; 18: 4969-4980.
34. Holtmann H., Enninga J., Kalble S., Thiefes A., Dorrie A., Broemer M., et al. The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J Biol Chem 2001 ; 276: 3508-3516.
35. Stoecklin G., Stubbs T., Kedersha N., Wax S., Rigby WF, Blackwell TK, et al. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. Embo J 2004 ; 23: 1313-1324.
36. Frevel MA, Bakheet T., Silva AM, Hissong JG, Khabar KS, Williams BR: p38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 2003 ; 23: 425-436.
37. Stoecklin G., Gross B., Ming XF, Moroni C.: A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 2003 ; 22: 3554-3561.
38. Laroia G., Cuesta R., Brewer G., Schneider RJ: Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 1999 ; 284: 499-502. (Pubitemid 29289625)
39. Jing Q., Huang S., Guth S., Zarubin T., Motoyama A., Chen J., et al. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 2005 ; 120: 623-634.
40. Vasudevan S., Steitz JA: AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 2007 ; 128: 1105-1118.
41. Eberhardt W., Doller A., Akool el S., Pfeilschifter J.: Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther 2007 ; 114: 56-73.
42. Behm-Ansmant I., Rehwinkel J., Doerks T., Stark A., Bork P., Izaurralde E.: mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 2006 ; 20: 1885-1898.
43. Wu L., Fan J., Belasco JG: MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006 ; 103: 4034-4039.
44. Giraldez AJ, Mishima Y., Rihel J., Grocock RJ, Van Dongen S., Inoue K., et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006 ; 312: 75-79.
45. Kerem E., Hirawat S., Armoni S., Yaakov Y., Shoseyov D., Cohen M., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008 ; 372: 719-727.
46. Hirawat S., Welch EM, Elfring CL, Northcutt VJ, Paushkin S., Hwang S., et al. Safety, tolerability, and pharmacokinetics of PTC124, a non-aminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007 ; 47: 430-444.
47. Jones S., Daley DT, Luscombe NM, Berman HM, Thornton JM: Protein-RNA interactions: a structural analysis. Nucleic Acids Res 2001 ; 29: 943-954.
48. Walter F., Vicens Q., Westhof E.: Aminoglycoside-RNA interactions. Curr Opin Chem Biol 1999 ; 3: 694-704.
49. Canzoneri JC, Oyelere AK: Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res 2008 ; 36: 6825-6834.
50. Gearhart MD, Dickinson L., Ehley J., Melander C., Dervan PB, Wright PE, et al. Inhibition of DNA binding by human estrogen-related receptor 2 and estrogen receptor alpha with minor groove binding polyamides. Biochemistry 2005 ; 44: 4196-4203.
51. Blackshaw S., St Croix B., Polyak K., Kim JB, Cai L.: Serial analysis of gene expression (SAGE): experimental method and data analysis. Curr Protoc Hum Genet 2007 Oct;Chapter 25:Unit 25B.6.
52. Liang P. A decade of differential display. Biotechniques 2002 ; 33: 338-344, 346.
53. Wong KK, McClelland M.: Stress-inducible gene of Salmonella typhimurium identified by arbitrarily primed PCR of RNA. Proc Natl Acad Sci USA 1994 ; 91: 639-643.
54. Waga I., Yamamoto J., Sasai H., Munger WE, Hogan SL, Preston GA, et al. Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy. Kidney Int 2003 ; 64: 1253-1264.
55. Meudt HM, Clarke AC: Almost forgotten or latest practice? AFLP applications, analyses and advances. Trends Plant Sci 2007 ; 12: 106-117.
56. Unger GM, Davis AT, Slaton JW, Ahmed K.: Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets 2004 ; 4: 77-84.
57. Mane SP, Evans C., Cooper KL, Crasta OR, Folkerts O., Hutchison SK, et al. Transcriptome sequencing of the Microarray Quality Control (MAQC) RNA reference samples using next generation sequencing. BMC Genomics 2009 ; 10: 264.
58. Ghosh S., Watson M., Collins J.: The relative transcription index: a gene expression based metric for prioritization of drug candidates. Comb Chem High Throughput Screen 2007 ; 10: 239-245.
59. Meisner NC, Hackermuller J., Uhl V., Aszodi A., Jaritz M., Auer M.: mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem 2004 ; 5: 1432-1447.
60. Sambrook J., Fritsch EF, Maniatis T.: Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
61. Innis MA: PCR Protocols: A Guide to Methods and Applications. San Diego: Academic Press, 1990.
62. Kastelic T., Cheneval D.: Assay for identifying compounds which affect stability of mRNA. WO 00/39314. Vancouver: Novation Pharmaceuticals, 1998.
63. Kastelic T., Schnyder J., Leutwiler A., Traber R., Streit B., Niggli H., et al. Induction of rapid IL-1 beta mRNA degradation in THP-1 cells mediated through the AU-rich region in the 3-2UTR by a radicicol analogue. Cytokine 1996 ; 8: 751-761.
64. Benjamin D., Colombi M., Moroni C.: A GFP-based assay for rapid screening of compounds affecting ARE-dependent mRNA turnover. Nucleic Acids Res 2004 ; 32: e89.
65. Digan ME, Pou C., Niu H., Zhang JH: Evaluation of division-arrested cells for cell-based high-throughput screening and profiling. J Biomol Screen 2005 ; 10: 615-623.
66. Rogers JT, Randall JD, Eder PS, Huang X., Bush AI, Tanzi RE, et al. Alzheimers disease drug discovery targeted to the APP mRNA 5untranslated region. J Mol Neurosci 2002 ; 19: 77-82.
67. Inglese J., Auld DS, Jadhav A., Johnson RL, Simeonov A., Yasgar A., et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006 ; 103: 11473-11478.
68. Bandyopadhyay S., Ni J., Ruggiero A., Walshe K., Rogers MS, Chattopadhyay N., et al. A high-throughput drug screen targeted to the 5untranslated region of Alzheimer amyloid precursor protein mRNA. J Biomol Screen 2006 ; 11: 469-480.
69. Greig NH, Giordano T., Zhu X., Yu QS, Perry TA, Holloway HW, et al. Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiol Exp (Wars) 2004 ; 64: 1-9.
70. Voon DC, Subrata LS, Baltic S., Leu MP, Whiteway JM, Wong A., et al. Use of mRNA- and protein-destabilizing elements to develop a highly responsive reporter system. Nucleic Acids Res 2005 ; 33: e27.
71. Bhattacharyya A., Trotta CR, Peltz SW: Mining the GEMS-a novel platform technology targeting post-transcriptional control mechanisms. Drug Discov Today 2007 ; 12: 553-560.
72. Paillusson A., Hirschi N., Vallan C., Azzalin CM, Muhlemann O.: A GFP-based reporter system to monitor nonsense-mediated mRNA decay. Nucleic Acids Res 2005 ; 33: e54.
73. Boelz S., Neu-Yilik G., Gehring NH, Hentze MW, Kulozik AE: A chemiluminescence-based reporter system to monitor nonsense-mediated mRNA decay. Biochem Biophys Res Commun 2006 ; 349: 186-191.
74. Warrior U., Fan Y., David CA, Wilkins JA, McKeegan EM, Kofron JL, et al. Application of QuantiGene nucleic acid quantification technology for high throughput screening. J Biomol Screen 2000 ; 5: 343-352.
75. Martel RR, Botros IW, Rounseville MP, Hinton JP, Staples RR, Morales DA, et al. Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay Drug Dev Technol 2002 ; 1: 61-71.
76. Canales RD, Luo Y., Willey JC, Austermiller B., Barbacioru CC, Boysen C., et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006 ; 24: 1115-1122.
77. Wong ML, Medrano JF: Real-time PCR for mRNA quantitation. Biotechniques 2005 ; 39: 75-85.
78. Heid CA, Stevens J., Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996 ; 6: 986-994.
79. Gibson UE, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 1996 ; 6: 995-1001.
80. Qin LX, Beyer RP, Hudson FN, Linford NJ, Morris DE, Kerr KF: Evaluation of methods for oligonucleotide array data via quantitative real-time PCR. BMC Bioinformatics 2006 ; 7: 23.
81. Kuo WP, Liu F., Trimarchi J., Punzo C., Lombardi M., Sarang J., et al. A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol 2006 ; 24: 832-840.
82. Wang Y., Barbacioru C., Hyland F., Xiao W., Hunkapiller KL, Blake J., et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006 ; 7: 59.
83. Willey JC, Crawford EL, Knight CR, Warner KA, Motten CA, Herness EA, et al. Standardized RT-PCR and the standardized expression measurement center. Methods Mol Biol 2004 ; 258: 13-41.
84. Vondracek M., Weaver DA, Sarang Z., Hedberg JJ, Willey JC, Warngard L., Grafstrom RC: Transcript profiling of enzymes involved in detoxification of xenobiotics and reactive oxygen in human normal and simian virus 40 T antigen-immortalized oral keratinocytes. Int J Cancer 2002 ; 99: 776-782.
85. To KK, Zhan Z., Litman T., Bates SE: Regulation of ABCG2 expression at the 3-2 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008 ; 28: 5147-5161.
86. Vogler H., Akbergenov R., Shivaprasad PV, Dang V., Fasler M., Kwon MO, et al. Modification of small RNAs associated with suppression of RNA silencing by tobamovirus replicase protein. J Virol 2007 ; 81: 10379-10388.
87. Gumireddy K., Young DD, Xiong X., Hogenesch JB, Huang Q., Deiters A.: Small-molecule inhibitors of microRNA miR-21 function. Angew Chem Int Ed Engl 2008 ; 47: 7482-7484.
88. Shan G., Li Y., Zhang J., Li W., Szulwach KE, Duan R., et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008 ; 26: 933-940.
89. Bandyopadhyay S., Sengupta TK, Fernandes DJ, Spicer EK: Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Biochem Pharmacol 2003 ; 66: 1151-1162.
90. Nair AP, Hahn S., Banholzer R., Hirsch HH, Moroni C.: Cyclosporin A inhibits growth of autocrine tumour cell lines by destabilizing interleukin-3 mRNA. Nature 1994 ; 369: 239-242.
91. Moreira AL, Sampaio EP, Zmuidzinas A., Frindt P., Smith KA, Kaplan G.: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993 ; 177: 1675-1680.
92. Knudsen P., Dinarello C., Strom T.: Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987 ; 139: 4129-4134.
93. Abdelmohsen K., Pullmann R. Jr, Lal A., Kim HH, Galban S., Yang X., et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 2007 ; 25: 543-557.
94. Baudouin-Legros M., Hinzpeter A., Jaulmes A., Brouillard F., Costes B., Fanen P., et al. Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3 UTR part of transcripts. Am J Physiol Cell Physiol 2005 ; 289: C1240-1250.
95. Mak IWY, Liu L., Ling V., Kastelic T. The effect of the fungal metabolite radicicol analog A on mRNA degradation. Genomics 2007 ; 90: 723-732.
96. Neininger A., Kontoyiannis D., Kotlyarov A., Winzen R., Eckert R., Volk HD, et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different posttranscriptional levels. J Biol Chem 2002 ; 277: 3065-3068.
97. Tran H., Maurer F., Nagamine Y.: Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 2003 ; 23: 7177-7188.
98. Linscheid P., Schaffner A., Schoedon G.: Modulation of inducible nitric oxide synthase mRNA stability by tetrahydrobiopterin in vascular smooth muscle cells. Biochem Biophys Res Commun 1998 ; 243: 137-141.
99. Chowdhury B., Tsokos CG, Krishnan S., Robertson J., Fisher CU, Warke RG, et al. Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3-2-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem 2005 ; 280: 18959-18966.
100. Brewer G., Ross J.: Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component. Mol Cell Biol 1989 ; 9: 1996-2006.
101. Levy AP, Levy NS, Goldberg MA: Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996 ; 271: 2746-2753.
102. Torrisani J., Unterberger A., Tendulkar SR, Shikimi K., Szyf M.: AUF1 cell cycle variations define genomic DNA methylation by regulation of DNMT1 mRNA stability. Mol Cell Biol 2007 ; 27: 395-410.
103. Matzinger SA, Chen B., Wang Y., Crist KA, Stoner GD, Kelloff GJ, et al. Tissue-specific expression of the K-ras allele from the A/J parent in (A/J - TSG-p53) F1 mice. Gene 1997 ; 188: 261-269.
104. Lee CH, Bradley G., Ling V.: Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability. Cell Growth Differ 1995 ; 6: 347-354.
105. Gherzi R., Trabucchi M., Ponassi M., Ruggiero T., Corte G., Moroni C., et al. The RNA-binding protein KSRP promotes decay of beta-catenin mRNA and is inactivated by PI3K-AKT signaling. PLoS Biol 2006 ; 5: e5.
106. Banholzer R., Nair AP, Hirsch HH, Ming XF, Moroni C.: Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3-2 untranslated region. Mol Cell Biol 1997 ; 17: 3254-3260.
107. Zaidi SH, Malter JS: Amyloid precursor protein mRNA stability is controlled by a 29-base element in the 3-2-untranslated region. J Biol Chem 1994 ; 269: 24007-24013.
108. Theodorakis NG, Morimoto RI: Posttranscriptional regulation of hsp70 expression in human cells: effects of heat shock, inhibition of protein synthesis, and adenovirus infection on translation and mRNA stability. Mol Cell Biol 1987 ; 7: 4357-4368.
109. Port JD, Huang LY, Malbon CC: β-Adrenergic agonists that down-regulate receptor mRNA up-regulate a Mr 35,000 protein(s) that selectively binds to β-adrenergic receptor mRNAs. J Biol Chem 1992 ; 267: 24103-24108.
110. Di Paola R., Frittitta L., Miscio G., Bozzali M., Baratta R., Centra M., et al. A variation in 3-2 UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet 2002 ; 70: 806-812.
111. Sessler AM, Kaur N., Palta JP, Ntambi JM: Regulation of stearoyl-CoA desaturase 1 mRNA stability by polyunsaturated fatty acids in 3T3-L1 adipocytes. J Biol Chem 1996 ; 271: 29854-29858.
112. Jain RG, Andrews LG, McGowan KM, Gao F., Keene JD, Pekala PP: Hel-N1, an RNA-binding protein, is a ligand for an A + U rich region of the GLUT1 3-2 UTR. Nucleic Acids Symp Ser 1995 ;(33). 209-211.
113. Mummidi S., Ahuja SS, McDaniel BL, Ahuja SK: The human CC chemokine receptor 5 (CCR5) gene: multiple transcripts with 5-2-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997 ; 272: 30662-30671.
114. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 2004 ; 65: 470-478.
115. Ing NH: Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. Biol Reprod 2005 ; 72: 1290-1296.
116. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004 ; 10: 1344-1351.
117. Abidi P., Zhou Y., Jiang JD, Liu J.: Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005 ; 25: 2170-2176.
118. Otake Y., Sengupta TK, Bandyopadhyay S., Spicer EK, Fernandes DJ: Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin down-regulation and destabilization of Bcl-2 mRNA. Mol Pharmacol 2005 ; 67: 319-326.
119. Otake Y., Sengupta TK, Bandyopadhyay S., Spicer EK, Fernandes DJ: Drug-induced destabilization of bcl-2 mRNA: a new approach for inducing apoptosis in tumor cells. Curr Opin Investig Drugs 2004 ; 5: 616-622.
120. Rikitake Y., Kim HH, Huang Z., Seto M., Yano K., Asano T., et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005 ; 36: 2251-2257.
121. Fujita J., Mestre JR, Zeldis JB, Subbaramaiah K., Dannenberg AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001 ; 7: 3349-3355.
122. Zhu X., Giordano T., Yu QS, Holloway HW, Perry TA, Lahiri DK, et al. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem 2003 ; 46: 5222-5229.
123. Rawlins P., Mander T., Sadeghi R., Hill S., Gammon G., Foxwell B., et al. Inhibition of endotoxin-induced TNF-alpha production in macrophages by 5Z-7-oxo-zeaenol and other fungal resorcylic acid lactones. Int J Immunopharmacol 1999 ; 21: 799-814.
124. Smoak K., Cidlowski JA: Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 2006 ; 26: 9126-9135.
125. Tucker S., Ahl M., Cho HH, Bandyopadhyay S., Cuny GD, Bush AI, et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res 2006 ; 3: 221-227.